Arcturus Therapeutics Holdings Inc. Common Stock (ARCT) Stock Price

ARCTStock

$15.44−22.53%52W

Market Cap$438.85M

P/E—

PEG Ratio—

Div yield—

Beta2.43

ARCT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)79.70%

Price vs S&P 500 (4W)146.34%

VGM Score63.58

Book Value / Share (Quarterly)$6.04

P/TBV (Annual)2.36x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-26.43%

Cash Flow / Share (Quarterly)$-2.56

Price vs S&P 500 (YTD)121.97%

Net Profit Margin (TTM)-317.62%

EPS (TTM)$-3.31

10-Day Avg Trading Volume1.68M

EPS Excl Extra (TTM)$-3.31

Revenue Growth (5Y)53.90%

EPS (Annual)$-2.40

ROI (Annual)-30.74%

Net Profit Margin (5Y Avg)-357.81%

Cash / Share (Quarterly)$6.74

Revenue Growth QoQ (YoY)-89.54%

ROA (Last FY)-24.26%

Revenue Growth TTM (YoY)-75.95%

EBITD / Share (TTM)$-3.55

ROE (5Y Avg)-32.16%

Operating Margin (TTM)-348.33%

Cash Flow / Share (Annual)$-2.62

P/B Ratio1.29x

P/B Ratio (Quarterly)1.11x

Net Income / Employee (Annual)$-620,600

EV / Revenue (TTM)1.05x

Net Interest Coverage (TTM)8.07x

ROA (TTM)-36.46%

EV / EBITDA (TTM)0.32x

EPS Incl Extra (Annual)$-2.40

Current Ratio (Annual)6.64x

Quick Ratio (Quarterly)5.76x

3-Month Avg Trading Volume0.60M

52-Week Price Return-22.53%

EV / Free Cash Flow (Annual)97.69x

Revenue / Employee (TTM)$277,000

Tangible BV / Share (Quarterly)$10.48

P/S Ratio (Annual)2.71x

Asset Turnover (Annual)0.30x

52-Week High$24.17

Operating Margin (5Y Avg)-362.44%

EPS Excl Extra (Annual)$-2.40

CapEx CAGR (5Y)-33.28%

Tangible BV CAGR (5Y)51.57%

26-Week Price Return90.95%

Quick Ratio (Annual)6.50x

13-Week Price Return104.27%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)5.88x

Enterprise Value$30.93M

Revenue / Share Growth (5Y)44.96%

Asset Turnover (TTM)0.11x

Book Value / Share Growth (5Y)-13.03%

Revenue / Employee (Annual)$773,900

Pretax Margin (Annual)-80.19%

Cash / Share (Annual)$8.13

3-Month Return Std Dev93.58%

Net Income / Employee (TTM)$-880,000

ROE (Last FY)-30.74%

Net Interest Coverage (Annual)19.72x

EPS Basic Excl Extra (Annual)$-2.40

P/FCF (TTM)1.07x

Receivables Turnover (TTM)3.09x

EV / Free Cash Flow (TTM)3.61x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-3.31

Receivables Turnover (Annual)17.20x

ROI (TTM)-46.54%

P/S Ratio (TTM)7.57x

Pretax Margin (5Y Avg)-357.47%

Revenue / Share (Annual)$3.00

Tangible BV / Share (Annual)$10.18

Price vs S&P 500 (52W)-40.84%

Year-to-Date Return133.93%

5-Day Price Return74.67%

EPS Normalized (Annual)$-2.40

ROA (5Y Avg)-20.90%

Net Profit Margin (Annual)-80.19%

Month-to-Date Return148.96%

Cash Flow / Share (TTM)$3.73

EBITD / Share (Annual)$-2.67

Operating Margin (Annual)-92.96%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-28.42%

LT Debt / Equity (Quarterly)0.06x

EPS Basic Excl Extra (TTM)$-3.31

P/TBV (Quarterly)2.28x

P/B Ratio (Annual)0.81x

Pretax Margin (TTM)-317.64%

Book Value / Share (Annual)$7.53

Price vs S&P 500 (13W)101.48%

Beta2.43x

P/FCF (Annual)9.17x

Revenue / Share (TTM)$1.03

ROE (TTM)-46.54%

52-Week Low$5.50

vGradeA

gGradeD

mGradeB

vgmGradeB

ARCT Earnings Surprise History

Q2 25-0.34est. -0.85

Q3 25-0.49est. -0.80

Q4 25-1.03est. -0.76

Q1 26-0.95est. -1.01

Q2 26-0.84est. -1.03

ARCT Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.05

4.06

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
ARCTArcturus Therapeutics Holdings Inc. Common Stock	A	D	B	$15.44
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Arcturus Therapeutics Holdings Inc. Common Stock

Arcturus Therapeutics develops mRNA medicines focused on infectious disease vaccines and rare liver and respiratory disease therapies. Its pipeline includes vaccine candidates for influenza and COVID-19 variants, as well as programs for rare genetic conditions. The company aims to address significant unmet medical needs in high-value therapeutic areas.